Selecta Biosciences Stock Forecast, Price & News

Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions

Is Selecta Biosciences a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Selecta Biosciences stock.
View analyst ratings for Selecta Biosciences or view top-rated stocks.

How has Selecta Biosciences' stock been impacted by COVID-19?

Selecta Biosciences' stock was trading at $3.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SELB shares have decreased by 6.1% and is now trading at $2.90.
View which stocks have been most impacted by COVID-19.

When is Selecta Biosciences' next earnings date?

Selecta Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Selecta Biosciences.

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences, Inc. (NASDAQ:SELB) announced its earnings results on Monday, November, 8th. The company reported ($0.16) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.09. During the same quarter last year, the firm posted ($0.09) earnings per share.
View Selecta Biosciences' earnings history.

What price target have analysts set for SELB?

7 Wall Street analysts have issued 1-year price objectives for Selecta Biosciences' shares. Their forecasts range from $3.50 to $13.00. On average, they anticipate Selecta Biosciences' stock price to reach $7.92 in the next year. This suggests a possible upside of 173.0% from the stock's current price.
View analysts' price targets for Selecta Biosciences or view top-rated stocks among Wall Street analysts.

Who are Selecta Biosciences' key executives?

Selecta Biosciences' management team includes the following people:

• Carsten Brunn, President, Chief Executive Officer & Director (LinkedIn Profile)
• Lloyd Johnston, COO, Senior Vice President-Research & Development
• Kevin Tan, Chief Financial & Accounting Officer
• Takashi Kei Kishimoto, Chief Scientific Officer
• Peter G. Traber, Chief Medical Officer (LinkedIn Profile)

Who are some of Selecta Biosciences' key competitors?

Some companies that are related to Selecta Biosciences include Nurix Therapeutics (NRIX), uniQure (QURE), Keros Therapeutics (KROS), Amneal Pharmaceuticals (AMRX), Organogenesis (ORGO), PureTech Health (PRTC), DICE Therapeutics (DICE), Antibe Therapeutics (ATBPD), Prometheus Biosciences (RXDX), Innoviva (INVA), MannKind (MNKD), Crinetics Pharmaceuticals (CRNX), MacroGenics (MGNX), Avidity Biosciences (RNA) and Day One Biopharmaceuticals (DAWN).
View all of SELB's competitors.

What other stocks do shareholders of Selecta Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD).

When did Selecta Biosciences IPO?

(SELB) raised $64 million in an initial public offering on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

What is Selecta Biosciences' stock symbol?

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Who are Selecta Biosciences' major shareholders?

Selecta Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.05%), Geode Capital Management LLC (1.50%), Two Sigma Advisers LP (1.30%), Goldman Sachs Group Inc. (1.13%), Two Sigma Investments LP (1.07%) and Deutsche Bank AG (0.52%). Company insiders that own Selecta Biosciences stock include Carsten Brunn, Lloyd P Johnston, Peter G Traber, Timothy A Springer, Timothy C Barabe and Timothy C Barabe.
View institutional ownership trends for Selecta Biosciences.

Which major investors are selling Selecta Biosciences stock?

SELB stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Millennium Management LLC, SG Americas Securities LLC, Two Sigma Investments LP, Goldman Sachs Group Inc., Renaissance Technologies LLC, Two Sigma Advisers LP, and Russell Investments Group Ltd.. Company insiders that have sold Selecta Biosciences company stock in the last year include Carsten Brunn, Lloyd P Johnston, and Peter G Traber.
View insider buying and selling activity for Selecta Biosciences or view top insider-selling stocks.

Which major investors are buying Selecta Biosciences stock?

SELB stock was purchased by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, BlackRock Inc., Connor Clark & Lunn Investment Management Ltd., Arrowstreet Capital Limited Partnership, Rafferty Asset Management LLC, UBS Group AG, Geode Capital Management LLC, and Opaleye Management Inc.. Company insiders that have bought Selecta Biosciences stock in the last two years include Peter G Traber, Timothy A Springer, and Timothy C Barabe.
View insider buying and selling activity for Selecta Biosciences or or view top insider-buying stocks.

How do I buy shares of Selecta Biosciences?

Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Selecta Biosciences' stock price today?

One share of SELB stock can currently be purchased for approximately $2.90.

How much money does Selecta Biosciences make?

Selecta Biosciences has a market capitalization of $338.28 million and generates $16.60 million in revenue each year. The company earns $-68.88 million in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Selecta Biosciences have?

Selecta Biosciences employs 44 workers across the globe.

What is Selecta Biosciences' official website?

The official website for Selecta Biosciences is selectabio.com.

Where are Selecta Biosciences' headquarters?

Selecta Biosciences is headquartered at 65 Grove Street, Watertown MA, 02472.

How can I contact Selecta Biosciences?

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The company can be reached via phone at (617) 923-1400, via email at [email protected], or via fax at 617-924-3454.